MEDICAL IMAGING’S ROLE IN THE DIAGNOSIS AND MANAGEMENT OF FATTY LIVER CLINICAL TRIALS
April 18, 2019 | (11:00 AM)
USA (United States of America)
Non-alcoholic steatohepatitis (NASH) is characterized by the presence of an abnormal accumulation of fat in the liver that can progress to cell injury and inflammation. Recent intervention studies have aimed to reduce the NASH-related metabolic stress and liver fat levels by decreasing the number of lipid droplets in the hepatocyte before inflammation and fibrosis become irreversible. Medical imaging is a powerful tool for measuring the effect of the intervention on liver fat. To incorporate effective imaging-based experiments into clinical trials for NASH, there are several factors to consider during the experimental design phase.